Skip to main content
Clinical Trials/NCT02729727
NCT02729727
Completed
Not Applicable

Clinical Study to Evaluate the CryoBalloon™ Full Ablation System for the Ablation of Human Esophageal Epithelium in Patients Undergoing Esophagectomy

Pentax Medical1 site in 1 country3 target enrollmentMarch 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Cancer
Sponsor
Pentax Medical
Enrollment
3
Locations
1
Primary Endpoint
Safety of CryoBalloon Ablation System
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

To evaluate the safety and treatment effect of the CryoBalloon™ Full Ablation System for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy

Detailed Description

The primary outcomes for the study are the safety and treatment effect of the CryoBalloon™ Ablation System. An esophagectomy will be performed as scheduled following the ablation procedure; histopathological analysis of surgically-resected specimens will be performed to determine the treatment effect.

Registry
clinicaltrials.gov
Start Date
March 2016
End Date
June 30, 2016
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Up to two (2) areas of 3 cm each non-ulcerated, columnar lined esophagus or squamous linted tissue suitable for ablation
  • Older than 18 years of age at the time of consent
  • Requires a clinically-necessary esophagectomy for esophageal cancer
  • Patient has provided written informed consent using the Informed Consent Form approved by the Institution's reviewing Medical Ethics Committee (MEC)

Exclusion Criteria

  • Patient refuses or is unable to provide written informed consent
  • Patient has esophageal narrowing limiting access to the intended site of ablation

Outcomes

Primary Outcomes

Safety of CryoBalloon Ablation System

Time Frame: through study completion, an average of 2 weeks

Incidence of device related serious adverse events

Secondary Outcomes

  • Device Performance(through study completion, an average of 2 weeks)

Study Sites (1)

Loading locations...

Similar Trials